Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

GP_Information

The trial results were announced at the European Society of Cardiology (ESC) Congress and published in JAMA on 29 August 2025. Read the results in our news item which also contains a patient-friendly animation.  

For all participants randomised into the Zio Patch arm of the study, once the patch was returned, the study team sent a letter to the participant’s GP practice containing information on the presence and duration of any episodes of atrial fibrillation. Participants also received a copy of this letter for their information.

Clinically significant findings were reported directly to the GP. The participant’s subsequent management is at the discretion of their GP, allowing the doctor and participant to discuss their management strategy (including anticoagulation) independently. The study team did not directly initiate treatment or act on the information from the Zio Patch data.

For further information, the 2024 European Society of Cardiology guidelines on the Management of Atrial Fibrillation can be found on the European Society of Cardiology (ESC) website.

There is also a Clinical Knowledge Summary produced by NICE available on the NICE website

Download the AMALFI protocol and the Statistical Analysis Plan for more information.